Krystal Biotech continues internal buildout with second facility 28-Jan-2020 By Ben Hargreaves The gene therapy company breaks ground on a backup facility ahead of the potential commercial launch of its lead therapy, B-VEC.
Krystal moves towards ‘full integration’ with gene therapy facility opening 07-Mar-2019 By Ben Hargreaves Krystal opens cGMP facility for the clinical and commercial manufacture of its lead drug candidate, KB103, and plans to open its second in 2020.
Bringing gene therapy manufacture in-house avoids ‘imbalanced’ CMO relationship 28-Jan-2019 By Ben Hargreaves The explosion of the gene therapy industry is leading to supply issues, which has led one company to view producing its own clinical materials as its best option.
